Moreover, the recent association of phenotypic and spatial characteristics of cancer-associated fibroblasts (CAFs) in the tumor microenvironment of NSCLC, with patient outcome [167], is worth exploring further in the context of RAF and MEK inhibitor targeted therapies in BRAF-mutant NSCLC. The gene discussed is MAP2K7; the disease is cancer.